Related Experiment Video
Updated: Sep 13, 2025
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Complement system modulation in age-related macular degeneration: navigating failures, building future successes
Aliénor Vienne-Jumeau1, Elodie Bousquet2, Francine Behar-Cohen3
1Centre hospitalier national d'ophtalmologie des Quinze-Vingts, Paris, France; Ophtalmopôle, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
Insights
Age-related macular degeneration (AMD) treatments targeting the complement system slow geographic atrophy but don't improve vision. Future therapies need earlier intervention and precision medicine for better outcomes in AMD.
Area of Science:
- Ophthalmology
- Immunology
- Genetics
Background:
- Age-related macular degeneration (AMD) is a primary cause of irreversible vision loss in older adults.
- Dysregulation of the complement system is linked to AMD development and progression.
- Current complement inhibition therapies are approved for geographic atrophy, a dry form of AMD.
Purpose of the Study:
- To review the current state of complement-targeted therapies for AMD.
- To identify challenges and future directions for AMD treatment.
Main Methods:
- Literature review of complement system involvement in AMD.
- Analysis of current complement inhibition therapies' efficacy and limitations.
- Discussion of emerging therapeutic strategies and biomarkers.
Main Results:
- Complement inhibitors moderately slow geographic atrophy lesion growth.
- Current treatments do not improve visual function.
- Significant challenges include intervention timing, delivery, safety, biomarkers, and response variability.
Conclusions:
- Complement modulation is a promising but complex therapeutic strategy for AMD.
- Future advancements require earlier intervention, precision medicine with genetic and imaging biomarkers.
- Exploring combination or gene-based therapies is crucial for improved AMD treatment outcomes.
Abstract:
Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in elderly populations across developed countries. Complement system dysregulation has been implicated in AMD onset and evolution. Complement inhibition therapies have been authorized in the USA as the primary treatment for geographic atrophy, the dry form of AMD. They have shown moderate efficacy in slowing geographic atrophy lesion growth but have not demonstrated improvements in visual function. Challenges remain, including the optimal timing of intervention, delivery routes, safety concerns, the lack of sensitive biomarkers to assess efficacy and guide patient selection, and variability in therapeutic response. Complement modulation represents a promising yet complex therapeutic avenue in AMD. Future success will require earlier intervention, precision medicine approaches integrating genetic and imaging biomarkers, and the exploration of combination or gene-based therapies.
Related Concept Videos
01:27Complement System
01:22iPS Cell Differentiation